Skye Bioscience Inc.(US:SKYE) TMX Newsfile·2026-01-05 17:46Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the Class Period from November 4, 2024, to October 3, 2025 [1][3]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Proceedings - Investors who purchased Skye securities during the Class Period have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. - The lawsuit claims that Skye failed to disclose that the efficacy of nimacimab was lower than previously represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Stock Performance - Following the announcement of topline data from a Phase 2a study on October 6, 2025, which revealed that the primary endpoint of an 8% weight loss difference compared to placebo was not met, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 [4].